dc.date.accessioned | 2024-01-19T17:42:29Z | |
dc.date.available | 2024-01-19T17:42:29Z | |
dc.date.created | 2023-06-16T10:29:44Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Brun, Marthe Kirkesæther Hammersbøen, Kristin Reine Viken, Marte Kathrine Stenvik, Grethe-Elisabeth Klaasen, Rolf Gehin, Johanna Warren, David John Sexton, Joseph Sandanger, Øystein Kvien, Tore Kristian Aaserud Mørk, Cato Haavardsholm, Espen A. Jahnsen, Jørgen Goll, Guro Løvik Lie, Benedicte Alexandra Bolstad, Nils Jørgensen, Kristin Kaasen Syversen, Silje Watterdal . HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases. Journal of Internal Medicine. 2023, 293(5), 648-655 | |
dc.identifier.uri | http://hdl.handle.net/10852/107030 | |
dc.description.abstract | Abstract Background Immunogenicity to tumour necrosis factor inhibitors is a significant clinical problem leading to treatment failure and adverse events. The study aimed to assess human leukocyte antigen (HLA) associations with anti‐drug antibody (ADAb) formation to infliximab. Methods Immune‐mediated inflammatory disease patients on infliximab therapy ( n = 612) were included. Neutralising ADAb were assessed with a drug‐sensitive assay. Next generation sequencing‐based HLA typing was performed. Results Overall, 147 (24%) patients developed ADAb. Conditional analyses indicated HLA‐DQB1 ( p = 1.4 × 10 −6 ) as a primary risk locus. Highest risk of ADAb was seen when carrying at least one of the HLA‐DQ2 haplotypes; DQB1*02:01–DQA1*05:01 or DQB1*02:02–DQA1*02:01 (OR 3.18, 95% CI 2.15–4.69 and p = 5.9 × 10 −9 ). Results were consistent across diseases and when adjusting for concomitant immunomodulator. Computational predictions indicated that these HLA‐DQ2 haplotypes bind to peptide motifs from infliximab light chain. Conclusion A genome‐wide significant association between two HLA‐DQ2 haplotypes and the risk of ADAb formation to infliximab was identified, suggesting that HLA‐DQ2 testing may facilitate personalised treatment decisions. | |
dc.language | EN | |
dc.publisher | Blackwell Science Ltd. | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases | |
dc.title.alternative | ENEngelskEnglishHLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases | |
dc.type | Journal article | |
dc.creator.author | Brun, Marthe Kirkesæther | |
dc.creator.author | Hammersbøen, Kristin Reine | |
dc.creator.author | Viken, Marte Kathrine | |
dc.creator.author | Stenvik, Grethe-Elisabeth | |
dc.creator.author | Klaasen, Rolf | |
dc.creator.author | Gehin, Johanna | |
dc.creator.author | Warren, David John | |
dc.creator.author | Sexton, Joseph | |
dc.creator.author | Sandanger, Øystein | |
dc.creator.author | Kvien, Tore Kristian Aaserud | |
dc.creator.author | Mørk, Cato | |
dc.creator.author | Haavardsholm, Espen A. | |
dc.creator.author | Jahnsen, Jørgen | |
dc.creator.author | Goll, Guro Løvik | |
dc.creator.author | Lie, Benedicte Alexandra | |
dc.creator.author | Bolstad, Nils | |
dc.creator.author | Jørgensen, Kristin Kaasen | |
dc.creator.author | Syversen, Silje Watterdal | |
cristin.unitcode | 185,53,44,10 | |
cristin.unitname | Ortopedisk avdeling - Ullevål | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |
dc.identifier.cristin | 2155194 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal of Internal Medicine&rft.volume=293&rft.spage=648&rft.date=2023 | |
dc.identifier.jtitle | Journal of Internal Medicine | |
dc.identifier.volume | 293 | |
dc.identifier.issue | 5 | |
dc.identifier.startpage | 648 | |
dc.identifier.endpage | 655 | |
dc.identifier.doi | https://doi.org/10.1111/joim.13616 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 0954-6820 | |
dc.type.version | PublishedVersion | |
dc.relation.project | NFR/328657 | |